CYSLTR2 and uveal melanoma: Montelukast, quininib and 1,4-dihydroxy quininib significantly inhibited uveal melanoma cells in a time- and dose-dependent manner, whereas a CysLT2-selective antagonist, HAMI 3379, did not show growth inhibition effect [81].